A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis

Trial Profile

A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs LCB01-0371 (Primary) ; Linezolid; Rifampicin/isoniazid/pyrazinamide/ethambutol
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Sponsors LegoChem Biosciences
  • Most Recent Events

    • 31 Aug 2017 Number of arms has changed from 3 to 5 ,hence patient number has alson changed from 30 to 64.
    • 28 Aug 2017 Planned number of patients changed from 30 to 64.
    • 28 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top